부산대학교 도서관

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jhep.2008.01.027 Byline: Stephanie Villet (1)(2), Christian Pichoud (1)(2), GaA'tan Billioud (1)(2), Luc Barraud (4), Sandra Durantel (4), Christian Trepo (1)(2)(3), Fabien Zoulim (1)(2)(3) Keywords: Pathogenesis; Antiviral-resistance; HBV variants; Phenotypic analysis; Cross-resistance Abbreviations: HBV, hepatitis B virus; LAM, lamivudine; ADV, adefovir; ETV, entecavir; LdT, telbivudine; YMDD, tyrosine, methionine, aspartate, aspartate; RT, reverse transcriptase; wt, wild-type; TDF, tenofovir; a.a., amino acid; IC, inhibitory concentration Abstract: Recent clinical observations reported the occurrence of amino acid substitutions at position 181 of the HBV polymerase, associated with a viral breakthrough under lamivudine or adefovir therapy. In this study, we characterized the main variants harboring the rtA181T/V mutation isolated from 10 consecutive patients who developed lamivudine and/or adefovir resistance. Author Affiliation: (1) INSERM, U871, Laboratoire des virus hepatiques et pathologies associees, Lyon F-69003, France (2) Universite Lyon 1, IFR62, Lyon Est F-69008, France (3) Hospices civils de Lyon, HA[acute accent]tel Dieu, Service d'Hepatologie, Lyon F-69002, France (4) Bioalliance Pharma, 49, boulevard General Martial Valin, Paris F-75015, France Article History: Received 31 October 2007; Revised 20 December 2007; Accepted 7 January 2008 Article Note: (footnote) [star] The authors declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript except Drs. Barraud and Durantel who are Bioalliance Pharma employees, France.